ArticleInternational journal of surgery (London, England)2026
Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgery remains the primary treatment for pancreatic ductal adenocarcinoma (PDAC), which has remarkably high morbidity and mortality rates. However, recurrence is prevalent after resection. The effectiveness of circulating tumor DNA (ctDNA) in recurrence prediction has been demonstrated, and methylation has advantages over traditional biomarkers in terms of early-stage specificity. These advances indicate the need for a ctDNA-based methylation marker for PDAC prognosis, which would be valuable in clinical practice.
methodsMIR129-2 promoter methylation markers were identified via a combination of differential methylation, differential expression, gene set enrichment analysis and survival analysis using TCGA data. A qPCR-based assay was developed to quantify MIR129-2 methylation in plasma samples with as little as 0.05% tumor DNA. Its performance in PDAC diagnosis and progression risk evaluation was evaluated using tissue (314 tumor vs. 306 normal) and plasma (187 PDAC vs. 59 normal) samples from two independent retrospective cohorts. A longitudinal cohort study (114 patients) was conducted to assess its performance in determining PDAC prognosis. Both before surgery and after surgery, plasma samples were collected.
resultsMIR129-2 methylation showed excellent performance in differentiating PDAC and normal tissues, with a sensitivity of 97.77% and a specificity of 98.71%. For the plasma samples, it had a high sensitivity of 87.20% and a specificity of 98.30%. Survival analysis revealed its ability to predict postoperative survival outcomes even in CA19-9-negative patients ( P = 0.001).
conclusionPostoperative measurement of ctDNA-based MIR129-2 methylation can be used to predict PDAC recurrence risk, offering a cost-effective assay to facilitate the postoperative management of PDAC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.